Overview

Update
IPO / Stock
Went Public on Jan 10, 2014 / NASDAQ:GLYC
Total Equity Funding
$86.38M in 4 Rounds from 7 Investors
Headquarters:
Gaithersburg, MD
Description:
GlycoMimetics is a biopharmaceutical company designing and developing small molecule therapeutics to treat various cancers.
Founders:
,
Categories:
Therapeutics, Health Care, Biotechnology
Website:
http://www.glycomimetics.com
Social:

Company Details

Update

GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.

Funding Rounds (4) - $86.38M

Update
DateAmount / RoundValuationLead InvestorInvestors
Oct, 2010$38.98M / Convertible Note0
Dec, 2009$38M / Series C5
Aug, 2004$5.1M / Series A6
May, 2003$4.3M / Series A4

Current Team (9)

Update

Offices/Locations (1)

Update
  • Headquarters

    101 Orchard Ridge Drive

    Suite 1E

    Gaithersburg, MD 20878

    USA

Images (1)

Update

Add Acquisitions

Add Board Members and Advisors

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos